What is the primary purpose of issuing 133,000,000 ordinary shares?

The primary purpose of issuing these shares is to facilitate BeOne Medicines Ltd.'s planned re-domiciliation from the Cayman Islands to Switzerland. The shares will be held by a subsidiary to satisfy outstanding equity awards granted under the company's 2016 Share Option and Incentive Plan.

What happens to these shares if the re-domiciliation to Switzerland does not proceed?

If the company's board of directors decides to abandon the re-domiciliation for any reason before it becomes effective, the 133,000,000 newly issued shares will be returned by the subsidiary to BeOne Medicines Ltd. for cancellation.

Does this transaction have any immediate tax implications for existing shareholders?

The filing indicates that the new shares will not be subject to Swiss issuance stamp tax or Swiss withholding tax because they are created, issued, and subscribed to prior to the completion of the re-domiciliation. There is no direct mention of immediate tax implications for existing shareholders outside of this. However, investors should consult with their own tax advisors regarding any potential implications.

ONC/BEIGF 8-K: Securities & Listing

Q: Are these new shares being registered with the SEC?

No, the new shares are being issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933. This means they are not being registered with the SEC.

Summary

BeOne Medicines Ltd. (ONC) filed an 8-K on May 13, 2025, detailing the issuance of 133,000,000 ordinary shares to its wholly owned subsidiary, BG NC 2, Ltd. This issuance is a component of the company's proposed re-domiciliation from the Cayman Islands to Switzerland, referred to as the 'Continuation.' These newly issued shares will be held by the subsidiary for the benefit of equity award holders under the Company's 2016 Share Option and Incentive Plan, intended to satisfy outstanding awards post-Continuation. The issuance of these shares is structured to avoid Swiss issuance stamp tax and withholding tax, as they will be fully created and issued before the Continuation. Importantly, these shares are being issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933. The company cautions that the actual outcomes may differ from forward-looking statements due to various risks, including clinical trial results, regulatory actions, and commercial success, as detailed in their SEC filings.

Key Highlights

1Issuance of 133,000,000 ordinary shares by BeOne Medicines Ltd. to its subsidiary BG NC 2, Ltd.
2Transaction is part of the company's planned re-domiciliation (Continuation) from Cayman Islands to Switzerland.
3New shares will be used to satisfy outstanding equity awards under the 2016 Share Option and Incentive Plan.
4Shares issued in reliance on the Section 4(a)(2) exemption from registration under the Securities Act of 1933.
5The company expects the issuance to be exempt from Swiss issuance stamp tax and withholding tax.
6If the Continuation is abandoned, the new shares will be cancelled.
7The filing includes standard forward-looking statements and risk factor disclaimers.

BeOne Medicines Ltd. 8-K Report, Unregistered Securities Sale (May 13, 2025)

Summary

Key Highlights

Frequently Asked Questions